A. Pflugfelder

发表

Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients

H. Rammensee, C. Garbe, G. Pawelec, 2009, Journal of immunotherapy.

Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma

A. Enk, J. Utikal, T. Holland-Letz, 2015, International journal of cancer.

Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses

J. Becker, C. Garbe, G. Pawelec, 2014, Cancer Immunology Research.

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis☆

P. Pollock, G. Mann, N. Hayward, 2015, EBioMedicine.

Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma

K. Ikenberg, C. Garbe, M. Berneburg, 2011, PloS one.

Lack of activity of betulin‐based Oleogel‐S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo‐controlled double‐blind phase II trial

C. Garbe, S. Krüger-Krasagakis, E. Stockfleth, 2015, The British journal of dermatology.

Cutaneous Metastases of Melanoma: New Treatment Options

C. Garbe, B. Weide, T. Eigentler, 2009 .

Genome-Wide Association Study Suggests the Variant rs7551288*A within the DHCR24 Gene Is Associated with Poor Overall Survival in Melanoma Patients

H. Soyer, D. Duffy, R. Sturm, 2022, Cancers.

High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk

H. Soyer, M. Stark, R. Sturm, 2019, The British journal of dermatology.

High response rate after intratumoral treatment with interleukin‐2

C. Garbe, G. Pawelec, C. Pföhler, 2010, Cancer.

High Response Rate After Intratumoral

C. Garbe, G. Pawelec, B. Weide, 2010 .

GSTP1 does not modify MC1R effects on melanoma risk

H. Soyer, D. Duffy, N. Martin, 2017, Experimental dermatology.

S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma

C. Garbe, B. Weide, F. Meier, 2013, Melanoma research.

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

M. Weichenthal, A. Hauschild, D. Schadendorf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

C. Garbe, P. Buttner, U. Leiter, 2012, British Journal of Cancer.

Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies.

C. Garbe, A. Forschner, U. Leiter, 2010, Clinics in dermatology.

Thirty-year history of palmar eruptions: A quiz. Palmar purpuric lichen nitidus.

K. Ikenberg, T. Biedermann, G. Metzler, 2011, Acta dermato-venereologica.

Incisional biopsy and melanoma prognosis: Facts and controversies.

C. Garbe, A. Forschner, U. Leiter, 2010, Clinics in dermatology.

S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version

M. Weichenthal, A. Hauschild, D. Schadendorf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Phenotypes and genotypes of melanoma patients

A. Pflugfelder, 2017 .

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.

J. Utikal, C. Berking, D. Schadendorf, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Genes determining nevus count and dermoscopic appearance in Australian melanoma cases and controls.

H. Soyer, M. Brown, D. Duffy, 2020, The Journal of investigative dermatology.

Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses

C. Garbe, E. Bierhoff, T. Dirschka, 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis

C. Garbe, A. Forschner, U. Leiter, 2013, PloS one.

Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up

C. Garbe, D. Schmidt, U. Leiter, 2011, Cancer Immunology, Immunotherapy.

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

F. D. De Braud, C. Garbe, D. Neri, 2011, Clinical Cancer Research.

Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group

C. Garbe, E. Stockfleth, D. Nashan, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

The role of radiotherapy in the overall treatment of melanoma.

C. Garbe, A. Forschner, F. Meier, 2013, Clinics in dermatology.

FC12 Long term follow-up of 72 melanoma patients after intratumoral treatment with interleukin-2: favorable survival and high rate of objective responses upon subsequent chemotherapy

C. Garbe, U. Leiter, C. Pföhler, 2010 .

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

J. Utikal, D. Schadendorf, A. Gesierich, 2021, Frontiers in Oncology.

BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy

C. Garbe, U. Leiter, J. Bauer, 2014, PloS one.

Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma

Andreas von Deimling, Jürgen Bauer, Christian Busch, 2014, PloS one.

Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour

C. Garbe, U. Leiter, J. Bauer, 2013, PloS one.

Melanoma staging: facts and controversies.

C. Garbe, A. Forschner, U. Leiter, 2010, Clinics in dermatology.

Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.

D. Schadendorf, C. Garbe, G. Pawelec, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

D. Schadendorf, C. Garbe, G. Pawelec, 2014, Clinical Cancer Research.

The MC1R r allele does not increase melanoma risk in MITF E318K carriers

J. Malvehy, D. Duffy, D. Whiteman, 2023, The British journal of dermatology.

Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses

J. Becker, C. Garbe, G. Pawelec, 2014, Cancer Immunology Research.

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

F. D. De Braud, C. Garbe, D. Neri, 2011, Clinical Cancer Research.

Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients

H. Rammensee, C. Garbe, G. Pawelec, 2009, Journal of immunotherapy.